Brokerages Set Sensus Healthcare, Inc. (NASDAQ:SRTS) PT at $6.88

Sensus Healthcare, Inc. (NASDAQ:SRTS) has received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.8750.

Several analysts have commented on the stock. Alliance Global Partners started coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They set a “buy” rating and a $7.50 target price for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, Maxim Group cut their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th.

Sensus Healthcare Price Performance

Shares of NASDAQ:SRTS opened at $3.92 on Friday. The stock has a market cap of $64.53 million, a price-to-earnings ratio of -8.34 and a beta of 1.22. The company has a 50 day moving average of $4.41 and a 200-day moving average of $3.98. Sensus Healthcare has a one year low of $3.03 and a one year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.10). Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. The business had revenue of $4.94 million during the quarter, compared to analyst estimates of $8.35 million. Equities research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

A number of hedge funds have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in Sensus Healthcare in the fourth quarter valued at approximately $77,000. Rothschild Wealth LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $500,000. Greenline Wealth Management LLC acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $513,000. Ingalls & Snyder LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at $219,000. Finally, State Street Corp increased its position in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after buying an additional 3,400 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.